Mini Focus on DiabetesThe Present and FutureJACC State-of-the-Art ReviewCardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review
The Present and Future
JACC State-of-the-Art Review
Under an Elsevier user license
open archive
Central Illustration
Key Words
diabetes
heart failure
renal function
SGLT2 inhibitor
Abbreviations and Acronyms
Ca2+
calcium
CI
confidence interval
FDA
U.S. Food and Drug Administration
GFR
glomerular filtration rate
GLP
glucagon-like peptide
HF
heart failure
HR
hazard ratio
Na+
sodium
NHE
sodium/hydrogen exchanger
RAAS
renin-angiotensin-aldosterone system
SGLT
sodium-glucose co-transporter
SGLT2i
sodium-glucose co-transporter 2 inhibitor
T1DM
type 1 diabetes mellitus
T2DM
type 2 diabetes mellitus
Cited by (0)
Dr. Zelniker has been funded by the Deutsche Forschungsgemeinschaft (ZE 1109/1-1). Dr. Braunwald has received grant support to his institution from Daiichi-Sankyo, AstraZeneca, GlaxoSmithKline, Merck, and Novartis; has provided uncompensated consultancies and lectures for Merck and Novartis; has received consulting fees from Theravance; and has received personal fees for lectures from Medscape.
© 2018 by the American College of Cardiology Foundation. Published by Elsevier.